NEWS
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.
Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly.
VitaPCR™ SARS-CoV-2 Related Assays Covers New Virus Strain
VitaPCR™ Influenza A&B/SARS-CoV-2 assay Receives CE Mark
Credo Diagnostics Biomedical VitaPCR™ SARS-CoV-2 Assay Garners CE Mark.
Credo Diagnostics Biomedical is finalizing a rapid point-of-care molecular test for the detection of novel Coronavirus COVID-19 in 20 minutes.